Cargando…
The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma
BACKGROUND: Insulin/insulin-like growth factor-1 signalling may underlie the promoting effect of type 2 diabetes on cancer. This study examined the association of diabetes, including steroid-induced diabetes (SID), and the impact of anti-diabetic medication on clinical outcomes of multiple myeloma (...
Autores principales: | Wu, W, Merriman, K, Nabaah, A, Seval, N, Seval, D, Lin, H, Wang, M, Qazilbash, M H, Baladandayuthapani, V, Berry, D, Orlowski, R Z, Lee, M-H, Yeung, S-C J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119980/ https://www.ncbi.nlm.nih.gov/pubmed/24921909 http://dx.doi.org/10.1038/bjc.2014.307 |
Ejemplares similares
-
Heparin-induced thrombocytopenia among patients of a comprehensive cancer center
por: Wu, Weixin, et al.
Publicado: (2014) -
Bayesian Joint Selection of Genes and Pathways: Applications in Multiple Myeloma Genomics
por: Zhang, Lin, et al.
Publicado: (2014) -
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
por: Wallis, Whitney D, et al.
Publicado: (2017) -
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
por: Shah, J J, et al.
Publicado: (2016) -
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer
por: Lu, Yunxia, et al.
Publicado: (2015)